Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
Clinical trial NCT01728376 · COMPLETED
Trial details
- NCT number
- NCT01728376
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2012-11-29
- Primary completion
- 2016-01-20
- Enrollment
- 82
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.